var data={"title":"Magnesium sulfate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Magnesium sulfate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6501?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Magnesium sulfate: Drug information&quot;</a> and <a href=\"topic.htm?path=magnesium-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Magnesium sulfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452590\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epsom Salt [OTC];</li>\n      <li>GoodSense Epsom Salt [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023184\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Magnesium Salt</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443860\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1,000 mg of magnesium sulfate = 98.6 mg <b>elemental</b> magnesium = 8.12 mEq magnesium = 4.06 mmol magnesium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate intake (AI):</b> Dose expressed as <b>elemental</b> <b>magnesium</b>: Oral: 30 mg daily; requirements may vary based on prematurity, postnatal age, and other clinical factors; serum magnesium concentrations should be monitored closely to determine patient-specific needs (IOM 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypomagnesemia: Note:</b> Dose depends on clinical condition and serum magnesium concentration; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>General dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>magnesium sulfate:</b> IM, IV: 25 to 50 mg/kg/dose every 8 to 12 hours for 2 to 3 doses (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>elemental magnesium:</b> IM, IV: 2.5 to 5 mg/kg/dose every 8 to 12 hours for 2 to 3 doses (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe (&lt;1.6 mg/dL or in presence of seizure due to neonatal hypocalcemia):</i> Dose expressed as <b>magnesium sulfate</b>: IV: 50 to 100 mg/kg/dose over 1 to 2 hours; may repeat dose in 12 hours if necessary (Cloherty 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, maintenance requirement:</b> Dose expressed as <b>elemental magnesium:</b> IV: 0.3 to 0.5 <b>mEq/kg</b>/day (ASPEN [Mirtallo 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Torsades de pointes, ventricular tachycardia:</b> Dose expressed as <b>magnesium sulfate</b>: IV, IO: 25 to 50 mg/kg/dose; if pulseless, administer as a bolus; if pulse, administer over 10 to 20 minutes (Hegenbarth 2008; PALS [Kleinman 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023211\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Magnesium sulfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>1,000 mg of magnesium sulfate = 98.6 mg <b>elemental</b> magnesium = 8.12 mEq magnesium = 4.06 mmol magnesium. <b>Note:</b> Serum magnesium is poor reflection of repletion status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI)</b> (IOM 1997): Dose expressed as <b>elemental</b> <b>magnesium</b>. Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 6 months: 30 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 to 12 months: 75 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA)</b> (IOM 1997): Dose expressed as <b>elemental</b> <b>magnesium</b>; during pregnancy and lactation, requirements may change: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: 80 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: 130 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 13 years: 240 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">14 to 18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Male: 410 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Female: 360 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypomagnesemia:</b> Infants, Children, and Adolescents: <b>Note:</b> Dose depends on clinical condition and serum magnesium concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>magnesium sulfate:</b> IV, IO: 25 to 50 mg /kg/dose every 6 hours for 2 to 3 doses, then recheck serum concentration; maximum dose: 2,000 mg/dose (Hegenbarth 2008; Kliegman 2011; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose expressed as <b>elemental magnesium:</b> IV: 2.5 to 5 mg/kg/dose every 6 hours for 2 to 3 doses (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation, occasional:</b> Oral: <b>Note</b>: With OTC use, should not exceed recommended treatment duration (7 days) unless directed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to &lt;12 years: 1 to 2 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 4 to 6 hours. Do not exceed 2 doses per day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 2 to 4 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 4 to 6 hours. Do not exceed 2 doses per day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition, maintenance requirement</b> (ASPEN [Mirtallo 2004]): Dose expressed as <b>elemental</b> <b>magnesium</b>: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;50 kg: 0.3 to 0.5 <b>mEq/kg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;50 kg and Adolescents: 10 to 30 <b>mEq/</b>day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Torsade de pointes or VF/pulseless VT associated with torsade de pointes:</b> Dose expressed as <b>magnesium sulfate:</b> IV: Infants, Children, and Adolescents: IV, IO: 25 to 50 mg/kg/dose; maximum dose: 2,000 mg /dose (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, acute refractory status:</b> Limited data available: Dose expressed as <b>magnesium sulfate</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents: 25 to 75 mg/kg/dose as a single dose; maximum dose: 2,000 mg/dose; recommended as adjunctive therapy in severe acute asthma for patients who have life-threatening exacerbations and in those whose exacerbations remain in the severe category after 1 hour of intensive conventional therapy (GINA 2014; Hegenbarth 2008; NAEPP 2007). Efficacy results variable. Two trials (Ciarallo 1996; Ciarallo 2000) showed significant improvement in pulmonary function in children who received a single dose of 25 mg/kg or 40 mg/kg magnesium sulfate vs. placebo; in another trial, pulmonary index scores after magnesium sulfate 75 mg/kg (maximum dose: 2,500 mg/dose) vs. placebo were not statistically different in 54 children between 1 to 18 years of age (Scarfone 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral inhalation: Nebulization (prepared from injectable formulation); given with a nebulized beta2-agonist (eg, albuterol): Limited data available: Optimal dose not established; efficacy results variable:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate asthma: Single dose: Children &ge;5 years and Adolescents: 2.5 mL isotonic magnesium sulfate solution mixed with albuterol 2.5 mg (0.5 mL) as a single dose. Magnesium was supplied as a 6.3% solution of magnesium heptahydrate, which is equivalent to anhydrous magnesium sulfate 3.18%. Doses were nebulized with 8 to 10 L/min of oxygen. Magnesium was found to have an additive effect on albuterol response (Mahajan 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe asthma: Three-dose series: Children &ge;2 years and Adolescents &le;16 years: 151 mg isotonic magnesium sulfate mixed with albuterol and ipratropium was administered every 20 minutes for 3 doses to patients with severe acute asthma who did not respond to standard inhalation treatment. In this large randomized, placebo-controlled trial (n=508, including 252 who received magnesium sulfate treatment; ages: 2 to 16 years) improvement was statistically significant, but clinically significant changes were only observed in the most severe patients (SaO2 &lt;92%) (Powell 2013). <b>Note:</b> Higher doses 500 mg magnesium sulfate mixed with albuterol (1 mL of 500 mg/mL parenteral solution and albuterol 1 mL nebulization solution mixed with 8 mL of distilled water; total volume: 10 mL) have been described for use in adolescents; however, the addition of magnesium showed no therapeutic benefit compared to albuterol alone (Aggarwal 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Dose represented as magnesium sulfate unless stated otherwise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>RDA</b> (IOM 1997): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults 19 to 30 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Females: 310 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pregnant females: 350 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Breast-feeding females: 310 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Males: 400 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;31 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Females: 320 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pregnant females: 360 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Breast-feeding females: 320 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Males: 420 mg elemental magnesium daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation, occasional:</b> Oral: 2 to 4 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 6 hours. Do not exceed 2 doses per day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypomagnesemia: Note:</b> Treatment depends on severity and clinical status. In asymptomatic patients (when oral route is available), oral replacement therapy is a better replacement method than IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild deficiency: IM: Manufacturer's labeling: 1,000 mg every 6 hours for 4 doses, or as indicated by serum magnesium concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate (serum concentration 1 to 1.5 mg/dL): IV: 1,000 to 4,000 mg (up to 125 mg/kg), administer at &le;1,000 mg/hour if asymptomatic; do not exceed 12 <b>g </b>over 12 hours (Kraft 2005). <b>Note:</b> Additional supplementation may be required after the initial dose with replenishment occurring over several days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe deficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: Manufacturer's labeling: Up to 250 mg/kg within a 4-hour period</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe (&lt;1 mg/dL): 4,000 mg to 8 <b>g</b> (up to 0.1875 g/kg), administer at &le;1,000 mg/hour if asymptomatic; in symptomatic patients, may administer &le;4,000 mg over 4 to 5 minutes (Kraft 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">With polymorphic VT (including torsade de pointes): IV push: 1,000 to 2,000 mg (ACLS [Neumar 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Obesity: Weight &gt;130% of ideal body weight (IBW) or body mass index (BMI) &ge;30 kg/m<sup>2</sup>: When determining maximum per kg dose for replacement, some clinicians suggest using adjusted body weight (AdjBW) (Kraft 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AdjBW (men) = ([wt (kg) -IBW (kg)] x 0.3) + IBW</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AdjBW (women) = ([wt (kg) -IBW (kg)] x 0.25) + IBW</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Eclampsia/preeclampsia (severe): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV: An initial total dose of 10 to 14 <b>g</b> administered as follows: 4,000 mg infusion with simultaneous IM injections of 4,000 to 5,000 mg in each buttock. After the initial IV/IM doses, may administer a 1,000 to 2,000 mg/hour continuous infusion or may follow with IM doses of 4,000 to 5,000 mg into alternate buttocks every 4 hours as necessary; maximum: 40 <b>g</b>/24 hours. IV use for preeclampsia/eclampsia is contraindicated during the 2 hours prior to delivery.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IV: 4,000 mg to 6 <b>g</b> loading dose followed by 1,000 to 2,000 mg/hour continuous infusion for at least 24 hours (ACOG 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition supplementation:</b> IV: 8 to 20 <b>mEq elemental</b> magnesium daily (ASPEN [Mirtallo 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Soaking aid:</b> Topical: Dissolve 2 cupfuls of granules per gallon of warm water; may also soak a towel with the solution to apply as a wet dressing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma:</b> IV: 2,000 mg as a single dose over 20 minutes (GINA 2015; NAEPP 2007); recommended as adjunctive therapy for severe life-threatening exacerbations and for exacerbations that remain severe after 1 hour of intensive conventional therapy (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Torsade de pointes or VF/pulseless VT associated with torsade de pointes:</b> IV, IO: 1,000 to 2,000 mg over 15 minutes (ACLS [Neumar 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypomagnesemia:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents: Use with caution; monitor closely for hypermagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Reduce dose by 50% (Kraft 2005). Use with caution; monitor for hypermagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preeclampsia/eclampsia:</i> Severe renal impairment: Per the manufacturer, do not exceed 20 grams during a 48-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191066\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Granules, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epsom Salt:  (454 g, 1810 g, 1816 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Epsom Salt:  (1810 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 1 g/50 mL in Dextrose 5% (50 mL); 1 g/50 mL in NaCl 0.9% (50 mL); 10 g/100 mL in Dextrose 5% (100 mL); 10 g/100 mL in NaCl 0.9% (100 mL); 10 g/250 mL in Dextrose 5% (250 mL); 10 g/250 mL in Lactated Ringers (250 mL); 10 g/500 mL (500 mL [DSC]); 2 g/100 mL in Dextrose 5% (100 mL); 2 g/100 mL in NaCl 0.9% (100 mL); 2 g/50 mL (50 mL); 2 g/50 mL in Dextrose 5% (50 mL); 2 g/50 mL in NaCl 0.9% (50 mL); 20 g/250 mL in Lactated Ringers (250 mL); 20 g/500 mL (500 mL); 20 g/500 mL in Dextrose 5% (500 mL); 20 g/500 mL in Lactated Ringers (500 mL); 25 g/250 mL in Lactated Ringers (250 mL); 3 g/50 mL in Dextrose 5% (50 mL); 3 g/50 mL in NaCl 0.9% (50 mL); 4 g/100 mL in Dextrose 5% (100 mL); 4 g/100 mL in NaCl 0.9% (100 mL); 4 g/50 mL (50 mL); 4 g/50 mL in Dextrose 5% (50 mL); 4 g/50 mL in NaCl 0.9% (50 mL); 40 g/1000 mL (1000 mL); 40 g/1000 mL in NaCl 0.9% (1000 mL); 40 g/500 mL in Dextrose 5% (500 mL); 40 g/500 mL in Lactated Ringers (500 mL); 5 g/100 mL in Dextrose 5% (100 mL); 50 g/500 mL in Lactated Ringers (500 mL); 50 mg/500 mL in Dextrose 5% (500 mL); 6 g/100 mL in Dextrose 5% (100 mL); 6 g/150 mL in NaCl 0.9% (150 mL); 6 g/50 mL in Dextrose 5% (50 mL); 6 g/50 mL in NaCl 0.9% (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191050\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963611\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Magnesium sulfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">1 g of magnesium sulfate = elemental magnesium 98.6 mg = magnesium 8.12 mEq = magnesium 4.06 mmol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Magnesium sulfate 1% [10 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.081 mEq/mL. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 2% [20 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.162 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 4% [40 mg/mL] in Water injection is equivalent to elemental magnesium 0.325 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 8% [80 mg/mL] in Water injection is equivalent to elemental magnesium 0.65 mEq/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium sulfate 50% injection is equivalent to elemental magnesium 4 mEq/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023217\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Must dissolve granules prior to administration. When used as a laxative, the patient should drink a full 8 ounces of liquid following each dose. Lemon juice may be added to the initial solution to improve the taste. <b>Note:</b> Most effective when taken on an empty stomach.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral inhalation: Nebulization: Mix injectable solution with albuterol &plusmn; ipratropium and administer over 10 to 20 minutes (Aggarwal 2006; Mahajan 2004; Powell 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Dilute prior to injection </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: May administer undiluted (50%) or may further dilute in a compatible fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Dilute in an appropriate fluid prior to administration. Rate of infusion dependent upon use: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For general replacement therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pediatric patients: Infuse slowly generally over 1 to 4 hours; in asymptomatic patients, a rate of &le;0.1 mEq/kg/hour may be considered (in adults, the usual rate is &le;1,000 mg/hour of <b>magnesium sulfate</b>); faster rates could be used up to a maximum infusion rate: 1 mEq/kg/hour (125 mg/kg/hour of <b>magnesium sulfate</b>);  rate should be slowed if patient experiences diaphoresis, flushing or a warm sensation (Corkins 2010; Kliegman 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Up to 50% of an IV dose may be eliminated in the urine; therefore, slower administration may improve retention (maximum rate: 1,000 mg/hour in asymptomatic patients). For doses &lt;6 <b>g</b>, infuse over 8 to 12 hours and for larger doses, infuse over 24 hours if patient asymptomatic. If patient is severely symptomatic (or has conditions such as preeclampsia or eclampsia) more aggressive therapy (&le;4,000 mg over 4 to 5 minutes) may be required; patients should be closely monitored (Kraft 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute/emergent therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pediatric patients:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Pulseless torsades or VT: May administer as a bolus (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hypomagnesemia or torsades with pulses: 10 to 20 minutes (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Status asthmaticus: 15 to 30 minutes (Ciarallo 1996; Ciarallo 2000; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Should generally be given no faster than 150 mg/minute; ACLS guidelines recommend administration over 15 minutes in patients with torsade de pointes (ACLS [Neumar 2010]). In cases of severe eclampsia with seizures, or persistent pulseless VT or VF with known hypomagnesemia faster rates (ie, over 1 to 2 minutes) may be necessary (Dager 2006). In patients not in cardiac arrest, hypotension and asystole may occur with rapid administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: After dilution, administer via an infusion pump</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Adult: Dissolve granules in warm water prior to use; may use as a soaking aid or for a compress. To make a compress, use a towel to apply as a wet dressing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191080\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to use, store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not freeze. Refrigeration of solution may result in precipitation or crystallization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023185\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Laxative for the relief of occasional constipation (OTC product: FDA approved in ages &ge;6 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment and prevention of hypomagnesemia (FDA approved in all ages); prevention and treatment of seizures in severe preeclampsia or eclampsia (FDA approved in pregnant females); has also been used IV and as an oral nebulization for adjunctive treatment of asthma exacerbation (severe, life-threatening) unresponsive to 1 hour of intensive conventional treatment and IV for treatment of torsade de pointes or VF/pulseless VT associated with torsade de pointes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Soaking aid for minor sprains and bruises (OTC product: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191104\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Magnesium sulfate may be confused with manganese sulfate, morphine sulfate </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MgSO<sub>4</sub> is an error-prone abbreviation (mistaken as morphine sulfate) </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191101\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects on neuromuscular function may occur at lower concentrations in patients with neuromuscular disease (eg, myasthenia gravis). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing (IV; dose related), hypotension (IV; rate related), vasodilation (IV; rate related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypermagnesemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191073\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any component of the formulation; heart block (see <b>Note</b>); myocardial damage; IV use for pre-eclampsia/eclampsia during the 2 hours prior to delivery (see <b>Note</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> Although the manufacturers' labeling for some IV formulations state use in pre-eclampsia/eclampsia during the 2 hours prior to (cesarean) delivery is contraindicated due to interaction with neuromuscular-blocking agents intraoperatively; stopping magnesium sulfate prior to cesarean delivery in these patients is not recommended and increases the risk of seizure. Instead, magnesium should be continued prior to and during the delivery (ACOG 2013). Additionally, the manufacturers' labeling for some IV formulations contraindicate the use of magnesium sulfate in the setting of heart block; however, the use of magnesium is appropriate in patients with serious conditions requiring magnesium therapy who either have mild degrees of heart block (eg, first degree) or more severe forms of heart block with a temporary or permanent cardiac pacemaker.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191054\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obstetrics: Vigilant monitoring and safe administration techniques (ISMP, 2005) recommended to avoid potential for errors resulting in toxicity. Monitor mother and fetus closely. Use longer than 5 to 7 days may cause adverse fetal events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Unlikely to effectively terminate irregular/polymorphic VT (with normal baseline QT interval) (AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte abnormalities:  Concurrent hypokalemia or hypocalcemia can accompany a magnesium deficit. Hypomagnesemia is frequently associated with hypokalemia and requires correction in order to normalize potassium. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral administration: Magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC Use): When used as a soaking aid, patients should not use if there is evidence of infection or prompt relief is not obtained. When used as a laxative, patients should consult a healthcare provider prior to use if they have: kidney disease; are on a magnesium-restricted diet; have abdominal pain, nausea, or vomiting; change in bowel habits lasting &gt;2 weeks; have already used a laxative for &gt;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017105\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299640\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191059\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12982&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May enhance the adverse/toxic effect of Magnesium Sulfate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4104770\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Increased alcohol intake can deplete magnesium stores (IOM, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191062\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013521\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002). Continuous maternal use for &gt;5 to 7 days (in doses such as those used for preterm labor, an off-label use) may cause fetal hypocalcemia and bone abnormalities, as well as fractures in the neonate. Magnesium sulfate injection is used for the prevention and treatment of seizures in pregnant or postpartum women with severe pre-eclampsia or eclampsia (ACOG 2013; ACOG 652 2016). Magnesium sulfate may also be used prior to early preterm delivery for neuroprotection to reduce the risk of cerebral palsy (ACOG 455 2010; ACOG 652 2016; Reeves 2011); specific regimens are not available, but treatment may be of benefit when birth is anticipated before 32 weeks gestation (ACOG 171 2016; ACOG 172 2016; ACOG 652 2016). Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth; maintenance therapy with tocolytics is ineffective and not recommended. Magnesium sulfate can be used up to 48 hours in women at risk of delivery within 7 days; however, it is not the preferred tocolytic (ACOG 171 2016; ACOG 652 2016). Magnesium sulfate injection may be used in conjunction with other tocolytics for neuroprotection; however, an increased risk of maternal complications may be observed when used in combination with some tocolytic agents (ACOG 171 2016). Magnesium toxicity should be suspected in pregnant women receiving magnesium in respiratory and/or cardiac arrest. Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023220\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Stool output (laxative use) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium concentrations if frequent or prolonged dosing required particularly in patients with renal dysfunction, calcium, and potassium concentrations; renal function</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Obstetrics: Patient status including vital signs, oxygen saturation, deep tendon reflexes, level of consciousness, fetal heart rate, maternal uterine activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023206\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Typical values: Total magnesium: 1.5 to 2.5 mEq/L </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191053\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">When taken orally, magnesium promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191072\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anticonvulsant: IM: 1 hour; IV: Immediate; Laxative: Oral: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of anticonvulsant activity: IM: 3-4 hours; IV: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Slow and poor (approximately one-third absorbed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%) (IOM 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 30%, to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as magnesium); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3426605\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Elemental Magnesium Content of Magnesium Salts</caption>\n      <col align=\"left\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Magnesium Salt</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Elemental Magnesium </p>\n            <p style=\"text-indent:0em;\">(mg/500 mg salt)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Magnesium</p>\n            <p style=\"text-indent:0em;\">(mEq/500 mg salt)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Magnesium chloride</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.9</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Magnesium gluconate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">27</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.4</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Magnesium L-aspartate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">49.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.1</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Magnesium oxide</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">302</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Magnesium sulfate</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">49.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.1</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323358\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/50 mL 5% (50 mL): $6.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/100ML 5% (100 mL): $8.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/50 mL 5% (50 mL): $6.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 5% (100 mL): $6.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/50 mL 5% (50 mL): $7.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/50 mL 5% (50 mL): $7.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/100ML 5% (100 mL): $7.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5GM/100ML 5% (100 mL): $9.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g/50 mL 5% (50 mL): $9.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/100ML 5% (100 mL): $10.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/100ML 5% (100 mL): $13.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/250ML 5% (250 mL): $14.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20GM/500ML 5% (500 mL): $22.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/500ML 5% (500 mL): $40.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50GM/500ML 5% (500 mL): $44.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50% (10 mL): $2.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $17.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/100 mL (100 mL): $8.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 gm/50 mL (50 mL): $8.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/500 mL (500 mL): $6.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/1000ML (1000 mL): $9.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate-Lact Ringers Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/250ML (250 mL): $14.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/500 mL (500 mL): $21.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20GM/250ML (250 mL): $22.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25GM/250ML (250 mL): $25.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/500 mL (500 mL): $36.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 g/500 mL (500 mL): $42.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Magnesium Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1GM/50ML 0.9% (50 mL): $6.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/100ML 0.9% (100 mL): $6.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2GM/50ML 0.9% (50 mL): $6.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3GM/50ML 0.9% (50 mL): $8.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/100ML 0.9% (100 mL): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4GM/50ML 0.9% (50 mL): $9.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/100ML 0.9% (100 mL): $9.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/150ML 0.9% (150 mL): $13.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6GM/50ML 0.9% (50 mL): $8.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10GM/100ML 0.9% (100 mL): $12.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40GM/L 0.9% (1000 mL): $41.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4088911\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cholal modificado (MX);</li>\n      <li>Inj. Magnesii Sulfurici (PL);</li>\n      <li>Kiddi Pharmaton (MX);</li>\n      <li>Magnesii Sulfas (PL);</li>\n      <li>Magnesii Sulfas Siccatus (PL);</li>\n      <li>Magnesium Sulfuricum (PL);</li>\n      <li>Magunesin (KR);</li>\n      <li>Vivioptal Junior (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;<i>Obstet Gynecol</i>, 2012, 119(6):1308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/22617615/pubmed\" target=\"_blank\" id=\"22617615\">22617615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aggarwal P, Sharad S, Handa R, Dwiwedi SN, Irshad M. Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. <i>Emerg Med J</i>. 2006;23(5):358-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/16627836 /pubmed\" target=\"_blank\" id=\"16627836 \">16627836 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;Committee Opinion No. 455: Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection,&quot; <i>Obstet Gynecol</i>, 2010, 115(3):669-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20177305/pubmed\" target=\"_blank\" id=\"20177305\">20177305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Task Force Report on Hypertension in Pregnancy. http://www.acog.org/Resources_And_Publications/Task_Force_and_Work_Group_Reports/Hypertension_in_Pregnancy. Updated 2013. Accessed February 3, 2014.16175681</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blitz M, Blitz S, Beasely R, et al, &quot;Inhaled Magnesium Sulfate in the Treatment of Acute Asthma,&quot; <i>Cochrane Database Syst Rev</i>, 2005, 19(4):CD003898.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/16235345 /pubmed\" target=\"_blank\" id=\"16235345 \">16235345 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloch H, Silverman R, Mancherje N, et al, &ldquo;Intravenous Magnesium Sulfate as an Adjunct in the Treatment of Acute Asthma,&rdquo; <i>Chest,</i> 1995, 107(6):1576-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7781349/pubmed\" target=\"_blank\" id=\"7781349\">7781349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo; <i>Crit Care Med</i>, 1982, 10(3):193-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7037303/pubmed\" target=\"_blank\" id=\"7037303\">7037303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheuk DK, Chau TC, and Lee SL, &quot;A Meta-analysis on Intravenous Magnesium Sulphate for Treating Acute Asthma,&quot; <i>Arch Dis Child</i>, 2005, 90(1):74-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15613519 /pubmed\" target=\"_blank\" id=\"15613519 \">15613519 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciarallo L, Brousseau D, and Reinert S, &ldquo;Higher-Dose Intravenous Magnesium Therapy for Children With Moderate to Severe Acute Asthma,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 2000, 154(10):979-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/11030848/pubmed\" target=\"_blank\" id=\"11030848\">11030848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciarallo L, Sauer AH, and Shannon MW, &ldquo;Intravenous Magnesium Therapy for Moderate to Severe Pediatric Asthma: Results of a Randomized, Placebo-Controlled Trial,&rdquo; <i>J Pediatr</i>, 1996, 129(6):809-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/8969721 /pubmed\" target=\"_blank\" id=\"8969721 \">8969721 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, Hansen AR eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins. 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum,</i> Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(12):1703-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/17125434/pubmed\" target=\"_blank\" id=\"17125434\">17125434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/documents/4. Updated April 2015. Accessed June 22, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,&rdquo; August 2007, <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idama TO and Lindow SW, &ldquo;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&rdquo; <i>Br J Obstet Gynaecol</i>, 1998, 105(3):260-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). Preventing magnesium toxicity in obstetrics. ISMP Acute Care Medication Safety Alert, October 20, 2005. Available at http://www.ismp.org/Newsletters/acutecare/articles/20051020.asp</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM). Dietary reference intakes for calcium, phosphorus, magnesium, vitamin d, and fluoride. National Academy of Sciences, Washington, DC, 1997. Available at <a href=\"http://fnic.nal.usda.gov/dietary-guidance/dri-reports/calcium-phosphorus-magnesium-vitamin-d-and-fluoride#overlay-context=dietary-guidance/dietary-reference-intakes/dri-reports\" target=\"_blank\">http://fnic.nal.usda.gov/dietary-guidance/dri-reports/calcium-phosphorus-magnesium-vitamin-d-and-fluoride#overlay-context=dietary-guidance/dietary-reference-intakes/dri-reports</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support (PALS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft MD, Btaiche IF, Sacks GS, et al, &ldquo;Treatment of Electrolyte Disorders in Adult Patients in the Intensive Care Unit,&rdquo; <i>Am J Health-Syst Pharm</i>, 2005, 62(16):1663-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/16085929/pubmed\" target=\"_blank\" id=\"16085929\">16085929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahajan P, Haritos D, Rosenberg N, Thomas R. Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma.<i> J Emerg Med</i>. 2004;27(1):21-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15219299 /pubmed\" target=\"_blank\" id=\"15219299 \">15219299 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15568296 /pubmed\" target=\"_blank\" id=\"15568296 \">15568296 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. <i>Emerg Med J</i>. 2007;24(12):823-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/18029512 /pubmed\" target=\"_blank\" id=\"18029512 \">18029512 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma. Clinical Practice Guidelines. National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support (ACLS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osada H, Watanabe Y, Nishimura Y, et al, &quot;Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,&quot; <i>Acta Obstet Gynecol Scand</i>, 2002, 81(10):931-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/12366483/pubmed\" target=\"_blank\" id=\"12366483\">12366483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell C, Kolamunnage-Dona R, Lowe J, et al. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. <i>Lancet Respir Med</i>. 2013;1(4):301-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/24429155 /pubmed\" target=\"_blank\" id=\"24429155 \">24429155 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeves SA, Gibbs RS, and Clark SL, &quot;Magnesium for Fetal Neuroprotection,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(3):202.1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/21376159/pubmed\" target=\"_blank\" id=\"21376159\">21376159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scarfone RJ, Loiselle JM, Joffe MD, et al, &ldquo;A Randomized Trial of Magnesium in the Emergency Department Treatment of Children With Asthma,&rdquo; <i>Ann Emerg Med</i>, 2000, 36(6):572-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/11097697/pubmed\" target=\"_blank\" id=\"11097697\">11097697</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12982 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452590\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1023184\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443860\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1023211\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F191066\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F191050\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963611\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1023217\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F191080\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1023185\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F191104\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F191101\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F191073\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F191054\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017105\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299640\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F191059\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F4104770\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F191062\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3013521\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1023220\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1023206\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F191053\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F191072\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F3426605\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323358\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4088911\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12982|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=magnesium-sulfate-drug-information\" class=\"drug drug_general\">Magnesium sulfate: Drug information</a></li><li><a href=\"topic.htm?path=magnesium-sulfate-patient-drug-information\" class=\"drug drug_patient\">Magnesium sulfate: Patient drug information</a></li></ul></div></div>","javascript":null}